Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 9/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800801 | 1.00 | PDK2 (0.46) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15940625 | 0.87 | HTR1A (0.57) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2541379 | 0.85 | PDE4D (0.46) | P2RX7LMNASMN1; SMN2IDO1 | |
| SCHEMBL2541376 | 0.85 | PDE4D (0.46) | P2RX7LMNASMN1; SMN2IDO1 | |
| SCHEMBL16803095 | 0.83 | ALDH1A1 (0.49) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16334947 | 0.82 | P2RX7 (0.37) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15528764 | 0.82 | CHRNB4 (0.45) | HTR1ASLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL2543396 | 0.80 | P2RX7 (0.40) | PDK2P2RX7LMNASMN1; SMN2IDO1 | |
| SCHEMBL2543401 | 0.80 | P2RX7 (0.40) | PDK2P2RX7LMNASMN1; SMN2IDO1 | |
| SCHEMBL12261625 | 0.80 | IDO1 (0.44) | HTR1ASLC6A2SLC6A4SLC6A3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4486722-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240417405-A1 | Substituted Spiro Derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-19 | — | — | US | disclosed |
| CN-119137101-A | Compounds, compositions, and methods | 尼科治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014207601-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207601-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| CN-1934100-A | Substituted quinazoline or pyridopyrimidine derivatives | BANYU PHARMA CO LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | PDK2 1184/4885HTR1A 4/4885SLC6A2 82/4885 |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | PDK2 4684/4885HTR1A 4331/4885SLC6A2 4696/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | PDK2 848/4885HTR1A 9/4885SLC6A2 55/4885 |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | PDK2 1995/4885HTR1A 144/4885SLC6A2 2305/4885 |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | PDK2 1995/4885HTR1A 144/4885SLC6A2 2305/4885 |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | PDK2 848/4885HTR1A 9/4885SLC6A2 55/4885 |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | PDK2 4267/4885HTR1A 1732/4885SLC6A2 2402/4885 |
| US-20240417405-A1 | Substituted Spiro Derivatives | BMI1, MLLT1, MLLT3 | PDK2 238/4885HTR1A 4298/4885SLC6A2 4864/4885 |
| US-20150005313-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | SNCA, DRD1, DRD2 | PDK2 655/4885HTR1A 22/4885SLC6A2 116/4885 |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | PDK2 15/4885HTR1A 2175/4885SLC6A2 1454/4885 |
| US-20150175573-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | PDK2 848/4885HTR1A 9/4885SLC6A2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.